Some agents have already been approved by U.S. FDA and the European Medicines Agency, such as VEGF-A targeting antibodies bevacizumab and ranibizumab, which now are widely used therapeutics in oncology and eye diseases, respectively [44,55,56]. The gene discussed is VEGFA; the disease is eye disorder.